NCT00231894View on ClinicalTrials.gov

Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
DiabetesSchizophreniaInsulin ResistanceCognitive Impairment
Interventions
DRUG

Pioglitazone

pioglitazone 30-45 mg/day

BEHAVIORAL

Life style diet group

life style diet education group 1x/week

OTHER

Placebo

placebo comparator capsules

Trial Locations (1)

10035

Nathan Kline Institute for Psychiatric Research, New York

All Listed Sponsors
lead

Nathan Kline Institute for Psychiatric Research

OTHER

NCT00231894 - Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia | Biotech Hunter | Biotech Hunter